- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
Can a New AI Tool Have an Impact in MRI Screening for Prostate Cancer?
In addition to segmentation of the prostate, the artificial intelligence (AI)-enabled advance reportedly facilitates PI-RADS scoring by assessing the size and intensity of possible lesions.
An emerging advance in segmenting and analyzing prostate lesions on magnetic resonance imaging (MRI) may help reduce the rate of misdiagnosis and enhance the efficiency of screening for prostate cancer.
Incorporating artificial intelligence (AI) technology, the new PI-RADS assistant (RSIP Vision) provides a baseline for scoring through the established Prostate Imaging Reporting and Data System (PI-RADS) with automated segmentation of the prostate as well as detection and analysis of lesions, according to the company.
RSIP Vision said the PI-RADS assistant assesses a variety of lesion parameters, including intensity, dimensions, and restriction, and enables objective follow-up comparison to lesions from previous MRI exams.
“Reviewing these scans accounts for a large portion of the radiologist’s workload. The PI-RADS assistant will significantly reduce examination time, improve scoring accuracy and precision, and ultimately lead to better clinical outcomes,” emphasized Rabeeh Fares, MD, a senior radiologist at the Tel-Aviv Sourasky Medical Center in Israel.
Dr. Fares, who was involved with the development of the PI-RADS assistant, noted that MRI screening has become increasingly popular for stratifying risk for prostate cancer due to the non-invasive nature of the imaging modality. In addition to a “huge influx of examinations” to report on, Dr. Fares said consistent reporting has been challenging in the past. He pointed out that one of the challenges was the potential of a patient to have scans from multiple MRI machines as the same imaging sequence may appear differently on different MRI devices.
“(This) has a direct effect on the image quality and image appearance,” added Dr. Fares. “This can make it challenging to report accurately, especially in follow-up exams.”
Dr. Fares also noted that variability in PI-RADS reporting has been an issue. He cited an example of two senior radiologists reporting the same lesion in an exam but assigning different PI-RADS scores. The automated objective measurements with the PI-RADS assistant should improve accuracy and consistency with PI-RADS scoring, according to Dr. Fares.
“This way, the whole management ‘wheel’ of prostate cancer patients can move faster and steadier,” noted Dr. Fares.
New Study Examines Short-Term Consistency of Large Language Models in Radiology
November 22nd 2024While GPT-4 demonstrated higher overall accuracy than other large language models in answering ACR Diagnostic in Training Exam multiple-choice questions, researchers noted an eight percent decrease in GPT-4’s accuracy rate from the first month to the third month of the study.
FDA Grants Expanded 510(k) Clearance for Xenoview 3T MRI Chest Coil in GE HealthCare MRI Platforms
November 21st 2024Utilized in conjunction with hyperpolarized Xenon-129 for the assessment of lung ventilation, the chest coil can now be employed in the Signa Premier and Discovery MR750 3T MRI systems.
FDA Clears AI-Powered Ultrasound Software for Cardiac Amyloidosis Detection
November 20th 2024The AI-enabled EchoGo® Amyloidosis software for echocardiography has reportedly demonstrated an 84.5 percent sensitivity rate for diagnosing cardiac amyloidosis in heart failure patients 65 years of age and older.
New Study Examines Agreement Between Radiologists and Referring Clinicians on Follow-Up Imaging
November 18th 2024Agreement on follow-up imaging was 41 percent more likely with recommendations by thoracic radiologists and 36 percent less likely on recommendations for follow-up nuclear imaging, according to new research.
